| Literature DB >> 29414687 |
Ismail Syed1, Jennifer Lee1, Pedro M Moraes-Vieira1, Cynthia J Donaldson2, Alexandra Sontheimer1, Pratik Aryal1, Kerry Wellenstein1, Matthew J Kolar2, Andrew T Nelson3, Dionicio Siegel3, Jacek Mokrosinski4, I Sadaf Farooqi4, Juan Juan Zhao1, Mark M Yore1, Odile D Peroni1, Alan Saghatelian2, Barbara B Kahn5.
Abstract
Palmitic acid hydroxystearic acids (PAHSAs) are endogenous lipids with anti-diabetic and anti-inflammatory effects. PAHSA levels are reduced in serum and adipose tissue of insulin-resistant people and high-fat diet (HFD)-fed mice. Here, we investigated whether chronic PAHSA treatment enhances insulin sensitivity and which receptors mediate PAHSA effects. Chronic PAHSA administration in chow- and HFD-fed mice raises serum and tissue PAHSA levels ∼1.4- to 3-fold. This improves insulin sensitivity and glucose tolerance without altering body weight. PAHSA administration in chow-fed, but not HFD-fed, mice augments insulin and glucagon-like peptide (GLP-1) secretion. PAHSAs are selective agonists for GPR40, increasing Ca+2 flux, but not intracellular cyclic AMP. Blocking GPR40 reverses improvements in glucose tolerance and insulin sensitivity in PAHSA-treated chow- and HFD-fed mice and directly inhibits PAHSA augmentation of glucose-stimulated insulin secretion in human islets. In contrast, GLP-1 receptor blockade in PAHSA-treated chow-fed mice reduces PAHSA effects on glucose tolerance, but not on insulin sensitivity. Thus, PAHSAs activate GPR40, which is involved in their beneficial metabolic effects.Entities:
Keywords: FAHFA; GLP-1 receptor; GPR40; glucose-insulin homeostasis; human islets; insulin secretion; palmitic acid hydroxystearic acid; type 2 diabetes
Mesh:
Substances:
Year: 2018 PMID: 29414687 PMCID: PMC5807007 DOI: 10.1016/j.cmet.2018.01.001
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287